Antibiotic resistance is a global problem with serious consequences for public health worldwide (1
). In this regard, in Peru, high levels of antimicrobial resistance have been reported in recent years, particularly in Gram-negative bacteria, most belonging to the Enterobacteriaceae
). In the Latin American region, although the presence of New Delhi metallo-β-lactamase (NDM-1)-producing Gram-negative bacteria has been documented in Argentina, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay, and Venezuela (4
), genomic studies conducted to characterize NDM producers have been limited (6–8
). We hereby report the draft genome sequence of the first NDM-1-producing Escherichia coli
strain (2ECMBL) in Peru, isolated in 2017 from a urine culture of an elderly patient with pancreatic cancer.
Genomic DNA of strain 2ECMBL was extracted using a PureLink quick gel extraction kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions. DNA quality and quantity were evaluated by agarose gel electrophoresis and by using a Qubit1 2.0 fluorometer (Life Technologies). The DNA library was prepared using a Nextera XT DNA library preparation kit (Illumina, Inc., Cambridge, UK), and genomic DNA was sequenced on an Illumina NextSeq PE platform using 150-bp paired-end reads, which yielded 345 contigs with an N50
value of 54,136 bp, a total number of assembled bases of 5,061,184 bp, and 84× coverage. De novo
genome assembly was performed using Velvet v.1.2.10, and the contigs were annotated by the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) v.3.2, whereas whole-genome sequence data were evaluated through bioinformatics tools (i.e., ResFinder v.3.0, VirulenceFinder v.1.5, MLST v.1.8, PlasmidFinder v.1.3, and pMLST v.1.4) available from the Center for Genomic Epidemiology (http://www.genomicepidemiology.org/
Multilocus sequence typing (MLST) showed that carbapenem-resistant E. coli 2ECMBL belongs to sequence type 155 (ST155), whereas identification of plasmid replicons revealed the carriage of IncFIB and IncA/C2 plasmids, with the IncF sequence belonging to the K-:A-:B1- type. Using a 90% threshold, resistance genes to β-lactams (blaPER-2, blaTEM-1B, blaNDM-1, and blaOXA-1), phenicols (catA2, cmIA1, and catB3), rifampin (arr-3), sulfonamides (sull, sul2, and sul3), tetracyclines (tetA), trimethoprim (dfrA31), aminoglycosides [aac(3)-Ia, aadA2, aadA1, aac(6´)lb-cr, strA, strB, and aac(3´)-lla], and fluoroquinolones [qnrVC1 and aac(6´)Ib-cr] were identified. In addition, the presence of the virulence genes ipfA (long polar fimbriae), gad (glutamate decarboxylase), and cma (colicin M) in the 2ECMBL strain was confirmed.
ST155 has been associated with humans and animals worldwide (9
), and specifically in Latin America, this lineage has been shown to be shared between avian pathogenic E. coli
(APEC) and human extraintestinal pathogenic E. coli
). Interestingly, to our knowledge, this is the first draft genome sequence of E. coli
ST155 recovered from an infected human in this region, highlighting the cocarriage of multidrug resistance determinants, including the clinically significant β-lactamase resistance genes blaNDM-1
In summary, this draft genome sequence provides valuable information that supports a better understanding and comparative genomic analysis of the dissemination of NDM-1-producing Enterobacteriaceae in clinical settings. In this regard, the emergence of strains of this sort in Peru is a cause for serious concern that supports the implementation of genomic surveillance studies in order to prevent the establishment of health care-associated infections (HAIs).
The genome sequence of E. coli
strain 2ECMBL has been deposited in DDBJ/ENA/GenBank under the project accession number PISG00000000